CNS Pharmaceuticals (CNSP) Assets Average (2019 - 2025)
CNS Pharmaceuticals' (CNSP) quarterly Assets Average came in at $10.2 million in Q4 2025, up 27.2% YoY from $8.1 million in Q4 2024, and down 22.31% on a QoQ basis from $13.2 million in Q3 2025.
CNS Pharmaceuticals (CNSP) Assets Average (2019 - 2025) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 7 years of Assets Average data on file, last reported at $10.2 million in Q4 2025.
- Quarterly Assets Average rose 27.2% year-over-year to $10.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.2 million (up 27.2% YoY) and the FY2025 annual result came in at $8.7 million, up 66.55% from the prior year.
- Assets Average slipped to $10.2 million in Q4 2025, from $13.2 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $14.5 million in Q1 2021 to a low of $1.7 million in Q1 2024.
- A 5-year average of $9.5 million and a median of $10.6 million in 2022 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2024 — Assets Average tumbled 83.58% — and 2025, when it surged 584.17%.
- Tracing CNSP's Assets Average over 5 years: stood at $10.1 million in 2021, then gained by 11.97% to $11.3 million in 2022, then plunged by 82.24% to $2.0 million in 2023, then soared by 299.87% to $8.1 million in 2024, then increased by 27.2% to $10.2 million in 2025.
- The last three Assets Average figures came in at $10.2 million (Q4 2025), $13.2 million (Q3 2025), and $14.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | CNS Pharmaceuticals | 2.65 Mn | -4.55 Mn | - | 10.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.25 Mn |
| Sep 30, 2025 | 13.19 Mn |
| Jun 30, 2025 | 14.13 Mn |
| Mar 31, 2025 | 11.23 Mn |
| Dec 31, 2024 | 8.06 Mn |
| Sep 30, 2024 | 4.94 Mn |
| Jun 30, 2024 | 2.07 Mn |
| Mar 31, 2024 | 1.68 Mn |
| Dec 31, 2023 | 2.01 Mn |
| Sep 30, 2023 | 4.39 Mn |
| Jun 30, 2023 | 6.93 Mn |
| Mar 31, 2023 | 10.23 Mn |
| Dec 31, 2022 | 11.35 Mn |
| Sep 30, 2022 | 11.04 Mn |
| Jun 30, 2022 | 14.16 Mn |
| Mar 31, 2022 | 12.31 Mn |
| Dec 31, 2021 | 10.13 Mn |
| Sep 30, 2021 | 12.87 Mn |
| Jun 30, 2021 | 13.69 Mn |
| Mar 31, 2021 | 14.50 Mn |